CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Researchers investigating growth hormone (GH) regulation in mammalian research models may consider experiments combining peptides that engage somatotroph cells of the anterior pituitary through complementary receptor systems. Two such peptides are CJC-1295 (Mod GRF 1-29) and Hexarelin. CJC-1295 (with DAC) is generally classified as a long-acting analog related to endogenous growth hormone–releasing hormone (GHRH) that engages the classical GHRH receptor

Hexarelin is typically described as a growth hormone secretagogue (GHS) acting at the ghrelin/secretagogue receptor in the same cells. Because the two peptides appear to target distinct receptors, co-exposure in cell-culture models is hypothesized to produce complementary actions, potentially altering both the amplitude and duration of GH output by pituitary cells relative to either peptide alone.

 

Research

CJC-1295 Interaction with GHRH Signaling

Researchers posit that CJC-1295 may engage somatotroph cells primarily through the GHRH receptor, which is considered the main receptor on the anterior pituitary cells regulating GH synthesis. According to Jetté et al., CJC-1295 is built on the core N-terminal GHRH(1–29) motif, which is generally regarded as the shortest fragment retaining substantial GHRH-receptor affinity. ⁽¹⁾

The peptide carries four amino acid substitutions intended to extend stability and preserve a bioactive conformation, which may reduce susceptibility to proteolytic enzymes such as dipeptidyl peptidase-IV and support more consistent receptor engagement in laboratory settings.

According to Jetté et al. DAC may have the potential to tether the peptide to albumin. DAC is an additional C-terminal lysine bearing an Nε-3-maleimidopropionamide moiety, commonly referred to as a drug-affinity complex, or “DAC.” Thus, when CJC-1295 is connected with DAC, this additionally promotes its stability and half-life beyond 72 hours. ⁽¹⁾

This albumin tethering is hypothesized to increase exposure time in the media and further reduce proteolysis, potentially prolonging the timing and duration of GHRH-receptor binding compared with non-DAC analogs. Mechanistically, GHRH-receptor engagement is generally thought to activate the cAMP pathway, which typically involves consecutive adenylyl cyclase, cAMP, and protein kinase A activation, as outlined by Culhane et al.^(2). Rising cAMP may then support phosphorylation events that promote calcium entry and the fusion of GH-containing secretory vesicles.

Because the DAC group is hypothesized to keep a fraction of the peptide associated with albumin in the media over time, researchers posit that the cAMP signal may be sustained longer than with shorter-acting GHRH analogs. Beyond acute release, GHRH-type signaling may also support the broader synthetic capacity of these cells. In another study of CJC-1295 with DAC, Alba et al. observed an apparent “increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry.“⁽³⁾

Hexarelin Interaction with Ghrelin/GHS-R1a Signaling

Rather than a GHRH analog, Hexarelin has been posited as a growth hormone secretagogue (GHS). It is a synthetic hexapeptide with the structure His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-N,H₂ and it was suggested by researchers such as Imbimbo et al. that it may stimulate GH re lease.⁽⁴⁾

Unlike GHRH analogs such as CJC-1295, Hexarelin appears to interact with a distinct receptor population called the growth hormone secretagogue receptor type 1a (GHS-R1a). Further experiments by Yin et al. describe this receptor as the principal receptor for the endogenous peptide g hrelin.⁽⁵⁾

According to their publication, upon binding GHS-R1a, the receptor is thought to couple with Gq/11 proteins, leading to activation of phospholipase C (PLC). The researchers also outlined that PLC may cleave membrane phospholipids into inositol-1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ is posited to mobilize Ca²⁺ from intracellular stores, while DAG may activate protein kinase C (PKC). The concurrent rise in cytosolic Ca²⁺ and PKC activity is then proposed to facilitate exocytosis of GH-containing granules.

Work in isolated cell systems is consistent with this PLC/PKC framework. Specifically, in studies of GHSs actions on cardiomyocytes, hexarelin and ghrelin were reported to act “through GHS-R1a receptor and protein kinase signalingng cascade,” and GHS-R antagonists apparently abolished this action. ⁽⁶⁾ Thus, Hexarelin appears to induce GH release through a mechanism distinct from, and potentially complementary to, the cAMP-driven pathway associated with GHRH analogs such as CJC-1295.

CJC-1295 & Hexarelin Potential on GH Output from Cells

Experiments suggest that GH release driven by either peptide may exceed the peaks typically observed under control conditions in laboratory settings. Importantly, Jetté et al. experimented with cultured anterior pituitary cells and apparently observed that CJC-1295 may produce an approximately 4-fold increase in GH area under the curve over a 2-hour window relative to hGRF(1–29) in their m odels.⁽¹⁾

Further research by Teichman et al. also suggested that a single exposure to the peptide may upregulate mean GH concentrations released by pituitary cells roughly 2- to 10-fold for extended periods of 6 days or more, with mean IGF-1 concentrations increasing approximately 1.5- to 3-fold for 9–11 days, and estimated the half-life of CJC-1295 with DAC at about 5.8–8. 1 days.⁽⁷⁾

This prolonged profile is generally attributed to the DAC-mediated albumin association described above, which is hypothesized to translate, in culture, into a longer window of elevated GHRH-receptor signaling. For Hexarelin, Imbimbo et al. conducted an evaluation suggesting the peptide may result in a strong but comparatively short-lived GH stimulus. In their work, the GH response of the evaluated cells to Hexarelin apparently produced an area under the curve roughly twice that of endogenous GHRH.⁽⁴⁾

The maximal stimulus from Hexarelin was posited to occur within roughly 30 minutes after evaluation. The combination of a sustained signal from CJC-1295 with DAC, with a transient pulse from Hexarelin, may be one reason researchers may consider the two peptides as potentially complementary in cell-culture models.

CJC-1295 & Hexarelin Synergistic Potential

To date, there appear to be no published laboratory experiments evaluating the specific combination of CJC-1295 and Hexarelin. However, the available literature has examined blends of Hexarelin with GHRH and related GHRH analogs, from which CJC-1295 is derived.

The most directly relevant data come from Arvat et al., who evaluated Hexarelin and GHRH individually and in combination. When evaluated alone, Hexarelin apparently generated a substantially larger GH area under the curve (about 2,200.8 ± 256.9 µg/L·h) than GHRH alone (around 792.2 ± 117.6 µg/L·h). On the other hand, when the two were combined, the apparently observed GH area under the curve rose to roughly 4,259.2 ± 308.0 µg/L·h, which the authors characterized as an apparent synergistic action, as it appears higher than the arithmetic sum of the two single-agent responses. ⁽⁸⁾

This pattern is consistent with the broader literature suggesting GHRH and GHS co-exposure may be supra-additive, which is an action generally attributed to the convergence of two distinct receptor pathways. Specifically, these are the cAMP/PKA for the GHRH receptor and PLC/IP₃/PKC for GHS-R1a, both acting on the same somatotroph cells.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. PMID: 15817669.
2. Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389fphar. .2015.00264. PMID: 26594176; PMCID: PMC4633518.
3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. PMID: 16822960.
4. Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-5. doi: 10.1007/BF00191904. PMID: 7957536.
5. Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427.
6. Sun Q, Ma Y, Zhang L, Zhao YF, Zang WJ, Chen C. Effects of GH secretagogues on contractility and Ca²⁺ homeostasis of isolated adult rat ventricular myocytes. Endocrinology. 2010 Sep;151(9):4446-54. doi: 10.1210/en.2009-1432.
7. Тeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. 2005-1536. PMID: 16352683.https://doi.org/10.1210jc
8. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Metabolism. 1997 Jan;46(1):83-8. doi: 10.1016/s0026-0495(97)90173-6. PMID: 9005975.